Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

This study has been terminated.
(Evidence of very low probability to success. No safety issues)
Sponsor:
Collaborator:
PRA International
Information provided by (Responsible Party):
sigma-tau i.f.r. S.p.A.
ClinicalTrials.gov Identifier:
NCT01567956
First received: March 28, 2012
Last updated: April 9, 2014
Last verified: April 2014

March 28, 2012
April 9, 2014
April 2012
October 2013   (final data collection date for primary outcome measure)
Proportion of clinical/endoscopic remissions [ Time Frame: End of treatment (week 8) ] [ Designated as safety issue: No ]
Remission will be defined according with the overall modified Mayo score (Disease Activity Index). A score ≤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score >1 will be considered necessary to classify the patient in remission state.
Same as current
Complete list of historical versions of study NCT01567956 on ClinicalTrials.gov Archive Site
  • Change from baseline in Rectal bleeding evaluation [ Time Frame: At week 2, 6 and 8 of treatment and after 4 week follow-up ] [ Designated as safety issue: No ]
    Evaluation will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).
  • Change from baseline in stool frequency evaluation [ Time Frame: At week 2, 6 and 8 of treatment and after 4 week follow-up ] [ Designated as safety issue: No ]
    Evaluations will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).
  • Histological response to the treatment [ Time Frame: End of treatment (week 8) ] [ Designated as safety issue: No ]
    Evaluated as an improvement of the histological index of at least 1 point
  • Change from baseline in C-reactive protein (CRP) and Fibrinogen [ Time Frame: End of the treatment (week 8) and after 4 week follow-up ] [ Designated as safety issue: No ]
  • Improvement of patients quality of life [ Time Frame: End of treatment period (week8) and after 4 week follow-up ] [ Designated as safety issue: No ]
    A validated specific questionnaire, the SIBDQ by McMaster university will be administered to evaluate changes in patients' quality of life
  • Haematology [ Time Frame: Baseline and end of treatment (week8) ] [ Designated as safety issue: Yes ]
    Haemoglobin, Haematocrit, RBC, WBC and differential count.
  • Electrocardiogram [ Time Frame: At baseline and at the end of treatment period (week8) ] [ Designated as safety issue: Yes ]
    Standard intervals (PR, RR, QRS, QT) will be collected plus all rhythm abnormalities
  • Adverse Events collection [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Serum Chemistry [ Time Frame: At baseline and at the end of treatment period (week8) ] [ Designated as safety issue: Yes ]
    Standard evaluation including renal and liver function, electrolytes and blood glucose
  • Change from baseline in Rectal bleeding evaluation [ Time Frame: At week 2, 6 and 8 of treatment and after 4 week follow-up ] [ Designated as safety issue: No ]
    Evaluation will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).
  • Change from baseline in stool frequency evaluation [ Time Frame: At week 2, 6 and 8 of treatment and after 4 week follow-up ] [ Designated as safety issue: No ]
    Evaluations will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).
  • Histological response to the treatment [ Time Frame: End of treatment (week 8) ] [ Designated as safety issue: No ]
    Evaluated as an improvement of the histological index of at least 1 point
  • Change from baseline in C-reactive protein (CRP) and Fibrinogen [ Time Frame: End of the treatment (week 8) and after 4 week follow-up ] [ Designated as safety issue: No ]
  • Improvement of patients quality of life [ Time Frame: End of treatment period (week8) and after 4 week follow-up ] [ Designated as safety issue: No ]
    A validated specific questionnaire, the SIBDQ by McMaster university will be administered to evaluate changes in patients' quality of life
  • Haematology [ Time Frame: Baseline and end of treatment (week8) ] [ Designated as safety issue: Yes ]
  • Electrocardiogram [ Time Frame: At baseline and at the end of treatment period (week8) ] [ Designated as safety issue: Yes ]
  • Adverse Events collection [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Serum Chemistry [ Time Frame: At baseline and at the end of treatment period (week8) ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study
Phase III Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment

The aim of the trial is to test safety, tolerability and efficacy of Propionyl-L-carnitine modified release tablets 1g/die in reducing the symptoms of the disease with respect to the proportion of patients with disease remission at the end of the 8 weeks of treatment. It will also aim to investigate capability of the treatment in the maintenance of remission after four weeks of treatment interruption; histological changes will be also evaluated and finally, improvement in the overall quality of life as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) will be investigated.

Although it seems clear that an abnormal function of the colonic epithelium is the central problem causing inflammation and the unusual immunological response to the normal gut flora in inflammatory bowel disease (IBD), the actual causes of these dysfunctions are still unknown. Short Chain Fatty Acids (SCFA) are the main fuel of the colonic epithelium, and are normally produced by the bacterial flora by fermentation of the complex carbohydrates forming non soluble fibers usually introduced with everyday diet. Butyrate alone contributes 70% of the normal colonocyte energy. Studies done using animal models and colonic mucosa biopsies from patients suffering form ulcerative colitis (UC) have consistently shown that a metabolic change occurs in diseased colonic mucosa, with an impairment of butyrate oxidation (and of beta-oxidation) and an energy shortage that is only incompletely compensated by oxidation of glucose and other substrates such as glutamine. It is also well known that matrix metalloproteases production is highly increased in IBD and that serum transglutaminase activity is significantly reduced in patients with IBD. Transglutaminases are enzymes contributing to the crosslinking of matrix proteins and the reduction seen in patients affected by IBD correlates well with the endoscopic and histopathologic grading in UC, meaning that part of the circulating enzyme is sequestered in the injured colonic tissue in the effort to re-build the extracellular matrix during the healing process. Propionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce membrane lipid peroxidation in endothelial cells from bovine aorta and coronary vessels, to reduce the effects of hypoxia in coronary endothelial cells, and to play a role in the cardiac metabolic abnormalities that contribute to the mechanical dysfunctions leading to heart failure. Given these properties of Propionyl-L-carnitine Hydrochloride (ST 261) and given the peroxidative damage suffered by colonocytes in UC together with their metabolic impairment, the use of this molecule for the treatment of UC seemed to be appropriate and sound, in particular as a carrier of a propionate moiety that, once transformed into succinate, enters the Kreb cycle, acting as an extra burst fuel improving the balance of energy production inside tissues. Previous clinical experience has shown that PLC promoted complete or nearly complete regression of cutaneous trophic ulcers in a large number of vasculopathic patients refractory to all other therapies. As far as the UC pathology is concerned, the effects of ST 261, given orally or intrarectally, were investigated at different dosages, in preclinical experimentation, either after a single trinitrobenzene sulphonic acid (TNBS) administration (acute colitis) or after repeated TNBS administrations (reactivated colitis). The results showed a reduction in the damaged colon area both in acute model and reactivated colitis, even if the beneficial effect of restoration of TNBS-induced alterations of tissue morphology is more evident in the reactivated colitis model, particularly after oral administration. Based on the above-described results a development plan in humans started to investigate the activity of PLC in the treatment of ulcerative colitis.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Ulcerative Colitis
  • Drug: Propionyl-L-Carnitine
    500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
  • Drug: Placebo
    500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
  • Experimental: Propionyl-L-Carnitine
    Modified release tablets containing 500 mg of propionyl-L-carnitine
    Intervention: Drug: Propionyl-L-Carnitine
  • Placebo Comparator: Placebo
    Modified release tablets containing inert substances
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
150
January 2014
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have read the Information for the Patient and signed the Informed Consent Form.
  • Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed endoscopically and histologically.
  • Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis), with rectal bleeding sub-score of at least 1.
  • Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening assessments.
  • If female, not pregnant or nursing. For women of childbearing potential, willingness to avoid a pregnancy during the treatment period and for at least 4 weeks from the last dose of drug and utilization of an efficient method of birth control for the entire duration of the trial and until the first menses after a 30-day period after the last dose of trial medication.

Exclusion Criteria:

  • Crohn's disease and indeterminate colitis.
  • Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.
  • Use of systemic antibiotics in the last 10 days preceding the screening.
  • Use of systemic Nonsteroidal anti-inflammatory drugs on a repeat basis in the last 10 days preceding the screening.
  • Use of probiotics started within 10 days preceding the screening. A stable regimen from at least 10 days prior to screening is allowed but the patient must be willing to continue up to the end of the study.
  • Use of immunosuppressants or biological agents within the last 6 weeks preceding the screening.
  • Treatment with L-carnitine or its esters derivatives within the last 3 months.
  • Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia, Campylobacter) or toxins (C.difficile).
  • Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed by the investigator.
  • History of colon resection.
  • Diverticulitis, symptomatic diverticulosis.
  • Active peptic ulcer disease.
  • Proctitis (extent of inflammation < 15 cm from the anus).
  • Bleeding disorders
  • Rectal therapy with any therapeutic enemas or suppositories with the exception of those required for endoscopy during the 10 days preceding the screening.
  • Active or chronic infection(s) or malignancies.
  • Known hypersensitivity to the active ingredient and excipients of the study drug
  • Patients treated with L-Carnitine or its esters derivatives during the 3 months preceding the screening phase.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Austria,   France,   Germany,   Hungary,   Latvia,   Lithuania,   Poland,   Spain
 
NCT01567956
ST261DM11006, 2011-004770-28
Yes
sigma-tau i.f.r. S.p.A.
sigma-tau i.f.r. S.p.A.
PRA International
Study Chair: Sandro Ardizzone, MD Head of Inflammatory Bowel Diseases Unit Hospital "Luigi Sacco" Milan - ITALY
sigma-tau i.f.r. S.p.A.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP